Condition (MeSH)
Pinealoma
ClinicalTrials.gov lists 66 trials for Pinealoma or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 11.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
66 of the 66 trials are tagged with Pinealoma itself; the rest are tagged with a narrower condition beneath it.
When did Pinealoma trials start? (29)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 3 |
| 2024 | 2 |
| 2023 | 2 |
| 2021 | 1 |
| 2020 | 1 |
| 2019 | 3 |
| 2018 | 2 |
| 2017 | 3 |
| 2016 | 2 |
Showing 10 of 29 earlier years.
No forecast is made for this condition: it averages 1.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; registered median of 54 months across 46 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Pinealoma trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 31 |
| Phase 1/2 | 4 |
| Phase 2 | 9 |
| Phase 3 | 2 |
| Not applicable | 6 |
| Observational | 13 |
| Expanded access | 1 |
How many Pinealoma trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 11 |
| Active, not recruiting | 2 |
| Completed | 38 |
| Terminated | 7 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Pinealoma trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 11 |
| National Institutes of Health Clinical Center (CC) | 3 |
| Children's Oncology Group | 1 |
Which drugs are being tested for Pinealoma? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cytoxan | 5 |
| Irinotecan | 4 |
| Thiotepa | 3 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| SOC: Temozolomide | 7 |
| or carboplatin | 4 |
| Filgrastime (G-CSF) | 3 |
| Etoposid | 3 |
| Cisplatin 1 | 2 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Pinealoma trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Neutrophil count decreased | 37 | 4 |
| Lymphocyte count decreased | 26 | 3 |
| Anemia | 17 | 4 |
| Vomiting | 16 | 7 |
| White blood cell decreased | 16 | 4 |
Showing 5 of 10 adverse events.
Which publications cover Pinealoma? (22)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. | Acta neuropathologica | 2020 | Yes |
| Melatonin Therapy Improves Cardiac Autonomic Modulation in Pinealectomized Patients. | Frontiers in endocrinology | 2020 | Yes |
| Incidence of pineal tumours. A review of the literature. | Neuro-Chirurgie | 2015 | Yes |
| Magnetic resonance imaging based morphologic evaluation of the pineal gland for suspected pineoblastoma in retinoblastoma patients and age-matched controls. | Journal of the neurological sciences | 2015 | Yes |
| Gamma knife surgery for pineal region tumors: an alternative strategy for negative pathology. | Arquivos de neuro-psiquiatria | 2014 | Yes |
Showing 5 of 22 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.